We are live on ! Find out more
UNCY icon

Unicycive Therapeutics
UNCY

15 hedge funds and large institutions have $992K invested in Unicycive Therapeutics in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

25% more funds holding

Funds holding: 12 → 15 (+3)

0.03% more ownership

Funds ownership: 0.77% → 0.79% (+0.03%)

33% less capital invested

Capital invested by funds: $1.48M → $992K (-$483K)

Holders
15
Holders Change
+3
Holders Change %
+25%
% of All Funds
0.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
1
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NCM
Nantahala Capital Management
Connecticut
+$85.1K
2
FNBT
FineMark National Bank & Trust
Florida
+$14.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$10.5K
4
Royal Bank of Canada
Royal Bank of Canada
Ontario, Canada
+$4.78K
5
UBS Group
UBS Group
Switzerland
+$4.29K

Top Sellers

Rank Fund Capital Flow
1
Truist Financial
Truist Financial
North Carolina
-$48K
2
BlackRock
BlackRock
New York
-$31K
3
Citadel Advisors
Citadel Advisors
Florida
-$21K
Name Holding Trade Value Shares
Change 		Change in
Stake
NCM
1
Nantahala Capital Management
Connecticut
$606K +$85.1K +8,905 +14%
BOTOTLSJU
2
Board of Trustees of The Leland Stanford Junior University
California
$205K – – –
AC
3
Ayrton Capital
Connecticut
$64K – – –
Geode Capital Management
4
Geode Capital Management
Massachusetts
$21K – – –
Vanguard Group
5
Vanguard Group
Pennsylvania
$19K – – –
FWM
6
Frontier Wealth Management
Missouri
$16K – – –
Citadel Advisors
7
Citadel Advisors
Florida
$13K -$21K -2,199 -59%
TCM
8
Tandem Capital Management
New Jersey
$13K – – –
FNBT
9
FineMark National Bank & Trust
Florida
$13K +$14.9K +1,563 New
Renaissance Technologies
10
Renaissance Technologies
New York
$9K +$10.5K +1,100 New
TRCT
11
Tower Research Capital (TRC)
New York
$4K +$1.27K +133 +35%
UBS Group
12
UBS Group
Switzerland
$4K +$4.29K +449 New
Royal Bank of Canada
13
Royal Bank of Canada
Ontario, Canada
$4K +$4.78K +500 New
SWM
14
Spire Wealth Management
Virginia
$1K +$955 +100 New
Truist Financial
15
Truist Financial
North Carolina
– -$48K -3,746 Closed
BlackRock
16
BlackRock
New York
– -$31K -2,417 Closed
Wells Fargo
17
Wells Fargo
California
– +$10 +1 +33%

UNCY Hedge Fund Activity: Q2 2022 in Review

15 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Unicycive Therapeutics (UNCY) for Q2 2022, worth a combined $992K — down 33% from $1.48M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new UNCY positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Nantahala Capital Management, adding an estimated $85.1K. The largest seller was Truist Financial, exiting entirely with an estimated $48K sold.

  • 15 institutional investors held Unicycive Therapeutics (UNCY) as of Q2 2022, up from 12 in Q1 2022.
  • Funds reported $992K of Unicycive Therapeutics stock for Q2 2022, down 33% quarter-over-quarter.
  • 5 funds opened new Unicycive Therapeutics positions in Q2 2022 and 2 closed out, a net change of +3 holders.
  • The largest Unicycive Therapeutics buyer in Q2 2022 was Nantahala Capital Management, an estimated $85.1K added.
  • The largest Unicycive Therapeutics seller in Q2 2022 was Truist Financial, an estimated $48K sold.

Based on aggregated 13F filings for Q2 2022.